Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease.

ABSTRACT:

Background and aims

Risk stratification after cure from hepatitis C virus (HCV) infection remains a clinical challenge. We investigated the predictive value of noninvasive surrogates of portal hypertension (liver stiffness measurement [LSM] by vibration-controlled transient elastography and von Willebrand factor/platelet count ratio [VITRO]) for development of hepatic decompensation and hepatocellular carcinoma in patients with pretreatment advanced chronic liver disease (ACLD) who achieved HCV cure.

Approach and results

A total of 276 patients with pretreatment ACLD and information on pretreatment and posttreatment follow-up (FU)-LSM and FU-VITRO were followed for a median of 36.6 months after the end of interferon-free therapy. FU-LSM (area under the receiver operating cha

SUBMITTER: Semmler G 

PROVIDER: S-EPMC8252110 | biostudies-literature | 2021 Apr

REPOSITORIES: biostudies-literature